Apyx Medical Corporation Common Stock (APYX) is a publicly traded Healthcare sector company. As of May 21, 2026, APYX trades at $3.79 with a market cap of $162.05M and a P/E ratio of -14.02. APYX moved -4.57% today. Year to date, APYX is +7.06%; over the trailing twelve months it is +154.36%. Its 52-week range spans $0.76 to $4.50. Analyst consensus is strong buy with an average price target of $6.00. Rallies surfaces APYX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Renuvion Combined with Liposuction Yields 50% Fewer Abdominoplasties, Higher Body-Q: Apyx Medical’s Renuvion combined with liposuction showed statistically higher patient-reported satisfaction (Body-Q 87.8 vs 73.8; p=0.03) and reduced abdominoplasty rates by over 50% (30.0% vs 67.1%) in a 113-patient retrospective study. Revision rates dropped to 12.0% versus 37.5% (p=0.038) with comparable complication rates (2.5% vs 2.7%).
| Metric | Value |
|---|---|
| Price | $3.79 |
| Market Cap | $162.05M |
| P/E Ratio | -14.02 |
| EPS | $-0.27 |
| Dividend Yield | 0.00% |
| 52-Week High | $4.50 |
| 52-Week Low | $0.76 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $52.84M |
| Net Income | $-11.11M |
| Gross Margin | 62.53% |
3 analysts cover APYX: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $6.00.